Tuberculosis & latent TB: the AU general practice approach

TB in an Australian general practice context

Tuberculosis may seem remote from everyday Australian general practice, but it appears regularly in clinics that see refugees, migrants, healthcare workers, and patients starting biologic therapies. Australia’s National TB Advisory Committee (NTAC) documents approximately 1,400 notified cases annually — roughly 6 per 100,000 population — placing Australia in the low-incidence category. The critical epidemiological fact is that more than 85% of those cases occur in overseas-born people, predominantly from sub-Saharan Africa, South and Southeast Asia (India, Vietnam, Philippines), the Pacific Islands, and Eastern Europe.

This shifts the clinical frame: in Australian general practice, TB risk assessment begins with birth country and recent travel, not community prevalence. A GP who asks “where were you born and raised?” and “have you spent time in a country where TB is common?” will catch the people most at risk.

The other core concept is the distinction between active TB and latent TB infection (LTBI). Active TB is a disease state — symptomatic, potentially infectious, and requiring six months of combination antibiotic therapy with state TB service support. LTBI is a contained immune state — asymptomatic, non-infectious, and managed in general practice with a short preventive regimen. Getting clear on which you are dealing with determines everything that follows.

Australia’s TB management framework rests on Therapeutic Guidelines, NTAC guidelines, and the CDNA Series of National Guidelines (SoNG) for Tuberculosis. State TB services are the operational backbone; they provide free drugs, contact tracing, specialist oversight, and directly observed therapy — the GP’s role is recognition, notification, and ongoing surveillance rather than independent treatment.

A. Core clinical — the AU general-practice framework

Recognising active TB

Active pulmonary TB — the most common form, accounting for roughly 75% of Australian cases — classically presents with a triad of chronic cough lasting more than three weeks, constitutional symptoms (fever, drenching night sweats, unexplained weight loss, anorexia, fatigue), and radiological findings of apical or upper-lobe infiltrate, sometimes with cavitation or pleural effusion. Haemoptysis, though less universal, is a red-flag symptom that should always prompt investigation in at-risk individuals.

The history should systematically cover:

• Country of birth and residence history — particularly time spent in countries with incidence above 40 per 100,000
• Contact history — exposure to anyone with known or suspected TB
• Immune status — HIV, diabetes mellitus (2–3× increased risk), current or recent immunosuppressive therapy (corticosteroids, anti-TNF biologics, JAK inhibitors, chemotherapy), renal dialysis
• Occupational risk — healthcare workers in high-risk settings, correctional facilities
• Social determinants — overcrowding, homelessness, alcohol use disorder, intravenous drug use, malnutrition

Extrapulmonary TB accounts for approximately 25% of cases and is more common in immunocompromised individuals. Forms include lymph node TB (most common extrapulmonary form — cervical, firm, matted nodes that may fistulate), pleural effusion (lymphocytic exudate, elevated adenosine deaminase), spinal TB or Pott’s disease (vertebral collapse, cold abscess), genitourinary TB (sterile pyuria, haematuria), miliary TB (haematogenous dissemination — diffuse fine nodular pattern on chest imaging), and CNS TB (TB meningitis with basal meningeal involvement, tuberculoma). Miliary and CNS TB are medical emergencies requiring urgent specialist referral.

Who to screen for LTBI

RACGP guidance on refugee and asylum seeker health and NTAC both support targeted LTBI screening in high-risk groups. Screen:

• Refugees and migrants from countries with TB incidence above 40 per 100,000 — post-arrival health assessment is the opportune moment
• HIV-positive individuals — lifetime reactivation risk rises to 50–80%; LTBI treatment is strongly recommended
• Close contacts of active pulmonary TB cases — household contacts and those who shared prolonged indoor air space
• Pre-immunosuppression — before starting anti-TNF biologics (infliximab, adalimumab, etanercept), JAK inhibitors, or significant corticosteroid therapy; before organ transplantation
• Healthcare workers with new IGRA or TST conversion
• Children under 5 who have had household contact with active TB
• Aboriginal and Torres Strait Islander people in selected communities where programmatic screening is operating

Do not screen the general low-risk Australian-born population — the pre-test probability is too low and false positives create unnecessary anxiety and treatment burden.

B. Diagnosis — active TB and LTBI

Investigating suspected active TB

eTG’s mycobacterial infections chapter outlines the standard workup:

Chest X-ray is the first step in any patient with symptoms suggesting pulmonary TB. Classic findings are apical or upper-lobe infiltrate, cavitation, hilar lymphadenopathy, or miliary nodules — but presentations vary considerably in immunocompromised patients.

Sputum studies are the diagnostic cornerstone:

• Sputum AFB smear (three early-morning specimens) — 50–70% sensitivity; positive result strongly supports the diagnosis and guides isolation decisions
• Xpert MTB/RIF (or Xpert Ultra) — rapid PCR that simultaneously detects Mycobacterium tuberculosis complex and rifampicin resistance; results within hours; high sensitivity and specificity
• Sputum culture — gold standard; provides full drug susceptibility testing; takes 2–6 weeks on liquid media

For patients unable to produce sputum spontaneously, bronchoscopy with bronchoalveolar lavage or biopsy is arranged by the specialist.

Blood tests in active TB include full blood count, CRP, liver function tests (baseline before therapy), urea and electrolytes, HIV test (mandatory — co-infection is common and substantially changes management), HbA1c, and vitamin D.

Notification to the state TB service should occur as soon as active TB is suspected — before culture confirmation — so that the public health response, including airborne isolation advice and contact tracing, can begin promptly.

Diagnosing LTBI

Two immunological tests detect TB-sensitised T-lymphocytes:

IGRA (QuantiFERON-TB Gold Plus or T-Spot.TB) measures interferon-gamma release from blood lymphocytes stimulated by MTB-specific antigens (ESAT-6 and CFP-10). It is the preferred test in BCG-vaccinated individuals because BCG vaccination causes no cross-reactivity. Advantages: single visit, no need to return for reading, more specific than TST. Limitations: cost, occasional indeterminate results (lymphopenia, specimen handling), and an 8-week window period after exposure.

Mantoux (TST) uses intradermal injection of 5 TU purified protein derivative (PPD). Read induration (not erythema) at 48–72 hours. Thresholds: ≥5 mm in HIV-positive or immunocompromised, ≥10 mm in high-risk populations including refugees and recent migrants. BCG vaccination causes false positives — use IGRA instead in BCG-vaccinated people.

Both tests have a window period of approximately 8 weeks after infection — repeat testing is appropriate if recent high-risk exposure is suspected. Neither test differentiates LTBI from active TB; the chest X-ray and symptom assessment do that.

A Medicare rebate applies to IGRA for specific indications including pre-biologic therapy, contact tracing, and refugee health assessment.

C. Treatment

Active TB — the six-month regimen

Standard drug-susceptible TB treatment per eTG comprises:

Intensive phase (2 months): Rifampicin + Isoniazid + Pyrazinamide + Ethambutol — the “RIPE” regimen. The four drugs cover for drug resistance while susceptibility results are awaited.

Continuation phase (4 months): Rifampicin + Isoniazid — once susceptibility is confirmed.

Adjuncts:

• Pyridoxine 25–50 mg daily with isoniazid — prevents peripheral neuropathy (mandatory)
• Corticosteroid adjunct (dexamethasone) for CNS TB — specialist decision
• Directly observed therapy (DOT) for patients with adherence concerns, children, and drug-resistant TB

Monitoring during therapy:

• Liver function tests at baseline and monthly — hepatotoxicity from rifampicin, isoniazid, and pyrazinamide is a significant risk
• Visual acuity and colour vision at baseline and monthly during ethambutol use — optic neuritis is the key toxicity
• Peripheral neuropathy monitoring with isoniazid
• Drug interactions review — rifampicin is a potent CYP enzyme inducer affecting warfarin, oral contraceptives, methadone, direct oral anticoagulants (DOACs), antiretrovirals, and calcineurin inhibitors; dose adjustment or alternative agents are often needed

MDR-TB (resistant to rifampicin and isoniazid) requires specialist tertiary management with regimens based on WHO 2024 BPaLM (bedaquiline + pretomanid + linezolid + moxifloxacin) — a six-month regimen now replacing older 18-month protocols.

LTBI treatment

WHO 2024 consolidated guidance places 3HP (rifapentine 900 mg + isoniazid 900 mg, taken together once weekly for 12 weeks) as the preferred regimen for most adults and children over 2 years. Key advantages over 9 months of daily isoniazid: shorter duration improves adherence, lower hepatotoxicity risk, and equivalent efficacy.

Pre-treatment checklist: exclude active TB (chest X-ray + symptom review), baseline liver function tests, HIV test, pregnancy test if relevant, full medication review for rifampicin/rifapentine interactions, and patient education about orange-tinged urine and sweat.

Alternative LTBI regimens:

• 4R (4 months daily rifampicin) — acceptable; lower hepatotoxicity than isoniazid-based; important drug interaction review required
• 6H or 9H (6 or 9 months daily isoniazid + pyridoxine) — still acceptable but less preferred given hepatotoxicity and long duration
• 3HR (3 months daily rifampicin + isoniazid) — intermediate option

State TB services typically supervise or co-manage LTBI treatment for high-risk individuals; private prescription is also possible for lower-risk patients.

D. Australian operations

State TB services

Each state and territory operates a TB control program providing:

• Free anti-TB drugs for active TB — regardless of Medicare eligibility, visa status, or ability to pay
• Contact tracing following mandatory notification
• Specialist consultation (respiratory physician, infectious disease specialist)
• DOT for adherence-complex cases
• Case management nursing support
• Refugee health liaison for post-arrival screening programmes

State programs include NSW TB Program, Victorian TB Program (Royal Melbourne Hospital), Queensland TB Control, WA TB Control, SA TB Service, and NT Centre for Disease Control. GP notification is the trigger that activates this infrastructure.

MBS and PBS

MBS Online items relevant to TB management:

• Standard consultation items 23/36/44 for assessment
• Item 715 (ATSI Health Assessment) — incorporates TB screening in relevant communities
• Refugee Health Assessment items 701/703/705/707 — post-arrival comprehensive assessment including LTBI screening
• GPCCMP items 965/967 — chronic disease management for post-TB lung disease sequelae
• Mental Health Care Plan items 2715/2717 — for psychological sequelae of prolonged illness or treatment

Anti-TB drugs for active TB are supplied through state TB services, not via the PBS. LTBI medications (rifampicin, isoniazid, pyridoxine) may be prescribed privately or through the state service. IGRA testing is Medicare-rebatable for high-risk indications including pre-biologic therapy and refugee assessment.

BCG vaccination

The Australian Immunisation Handbook recommends BCG on a selective rather than universal basis: neonates with planned travel to high-incidence countries, selected Aboriginal and Torres Strait Islander infants in high-risk communities, and some healthcare workers in high-risk settings. BCG provides modest protection in children against severe disseminated forms of TB (miliary, CNS) but does not reliably prevent pulmonary TB in adults.

E. Special populations

HIV co-infection is the single most powerful risk factor for TB reactivation — lifetime reactivation risk rises from ~10% to 50–80%. Active TB is the leading infectious cause of mortality in HIV. LTBI treatment is strongly recommended for all HIV-positive individuals with positive IGRA or TST. Antiretroviral therapy and TB therapy can generally proceed simultaneously; however, immune reconstitution inflammatory syndrome (IRIS) risk must be considered when CD4 counts are very low.

Pregnancy: Active TB is treatable in pregnancy with RIPE (avoiding streptomycin, which is ototoxic to the fetus). Pyridoxine is particularly important. LTBI treatment may be deferred until after delivery in lower-risk pregnant individuals; in HIV co-infection or high reactivation risk, treatment proceeds in pregnancy.

Children under 5 in household contact with active TB should receive LTBI prophylaxis even with an initial negative IGRA or TST, because the window period and lower test sensitivity in young children mean a negative result does not exclude infection. Specialist paediatric infectious disease input is appropriate.

Aboriginal and Torres Strait Islander communities — historically higher TB rates are reducing with public health programs, but TB screening remains part of comprehensive health assessments in high-prevalence communities. Use item 715 proactively.

When to escalate

Refer or escalate immediately when:

• Active TB is suspected — notify the state TB service and arrange urgent specialist review; airborne isolation precautions apply for sputum-smear-positive pulmonary TB
• Extrapulmonary TB is suspected — lymph node, CNS, miliary, or spinal forms require specialist assessment
• Drug-resistant TB (MDR or XDR) — tertiary centre and state service management; do not attempt to manage independently
• HIV co-infection — co-management with HIV specialist
• Paediatric TB — paediatric infectious disease specialist
• LTBI management uncertainty — state TB service for advice on regimen choice or drug interactions
• Severe hepatotoxicity during treatment — hepatotoxicity with ALT more than five times the upper limit of normal warrants treatment interruption and specialist review

What this article is and is not

This is general health information drawn from Australian TB control guidelines — NTAC, eTG, CDNA SoNG, Australian Immunisation Handbook, RACGP refugee health guidance, and WHO 2024 consolidated TB guidelines. It is not personal medical advice and does not create a doctor–patient relationship. Active TB management in Australia is coordinated through state TB services; this article is intended to support GP recognition and notification, not to replace specialist oversight.

For consumer-level information: HealthDirect — Tuberculosis and Better Health Channel — Tuberculosis.

For public health and TB service contacts: Australian Government — TB programs and contacts.

---

Sources cited

1. National TB Advisory Committee (NTAC) — Australian TB control guidelines
2. CDNA SoNG — Tuberculosis
3. Therapeutic Guidelines (eTG) — Antibiotic: mycobacterial infections
4. Australian Medicines Handbook
5. Australian Immunisation Handbook — BCG
6. RACGP — Refugee and asylum seeker health
7. Australasian Society of Infectious Diseases (ASID) — Refugee Health
8. WHO — Consolidated guidelines on tuberculosis (2024 update)
9. HealthDirect — Tuberculosis
10. Better Health Channel — Tuberculosis
11. MBS Online